Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System by Dos Santos, Jéssica Barreto Ribeiro et al.
Dos Santos, Jéssica Barreto Ribeiro and Almeida, Alessandra Maciel 
and Acurcio, Francisco De Assis and De Oliveira, Haliton Alves and 
Kakehasi, Adriana Maria and Guerra, Augusto Afonso and Bennie, 
Marion and Godman, Brian and Alvares, Juliana (2016) Comparative 
effectiveness of adalimumab and etanercept for rheumatoid arthritis in 
the Brazilian Public Health System. Journal of Comparative 
Effectiveness Research, 5 (6). pp. 539-549. ISSN 2042-6305 , 
http://dx.doi.org/10.2217/cer-2016-0027
This version is available at https://strathprints.strath.ac.uk/59519/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
 Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis treatment in the 
Brazilian Public Health System (SUS) 
 
Jéssica Barreto Ribeiro dos Santos1, Alessandra Maciel Almeida2, Francisco de Assis Acurcio2, 
Haliton Alves de Oliveira Junior1, Adriana Maria Kakehasi3, Augusto Afonso Guerra Junior2, Marion 
Bennie4, Brian Godman4,5*, Juliana Alvares2 
 
1Postgraduate Program in Medicines and Pharmaceutical Assistance, College of Pharmacy, Federal 
University of Minas Gerais, Av. Presidente Antônio Carlos, 6627 Campus Pampulha, Belo Horizonte, 
Minas Gerais 31270-901, Brazil. Emails: jessica_oterrab@hotmail.com; halitonjr@hotmail.com 
2College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos, 6627 
Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil. Emails: 
alessandraalm@gmail.com; fracurcio@gmail.com; augustoguerramg@gmail.com; 
jualvares@gmail.com 
3Medicine School, Federal University of Minas Gerais, Av. Prof. Alfredo Balena, 190, Belo Horizonte, 
Minas Gerais 30130-100, Brazil. Email: amkakehasi@gmail.com 
4Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. 
Emails: marion.bennie@strath.ac.uk; Brian.Godman@strath.ac.uk 
5Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden. Email: 
Brian.Godman@ki.se 
 
*Author for correspondence: Brian Godman, Strathclyde Institute of Pharmacy and Biomedical 
Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom. Email:  
brian.godman@strath.ac.uk. Telephone: 0141 548 3825. Fax: 0141 552 2562 and Division of Clinical 
Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, 
Sweden. Email: Brian.Godman@ki.se. Telephone + 46 8 58581068. Fax + 46 8 59581070 
 
(Accepted for publication in Journal of Comparative Effectiveness Research ± Please keep 
CONFIDENTIAL) 
 
ABSTRACT 
Introduction: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are used to treat 
rheumatoid arthritis (RA). Adalimumab and etanercept were the most used bDMARDs in Brazil. 
Objective: This open prospective cohort study evaluated adalimumab and etanercept among RA 
patients in the Brazilian Public Health System. The Clinical Disease Activity Index was primarily used 
to assess their effectiveness after 6 and 12 months of follow-up. Results: 266 RA patients started 
treatment with adalimumab or etanercept. Adalimumab was the most widely used bDMARD (70%). 
46% achieved remission or low disease activity at 12 months with no difference of effectiveness 
between them (p=0.306). bDMARDs were more effective in patients who had better functionality at 
treatment onset and had spent longer in education. Conclusion: This real-world study demonstrated 
that adalimumab and etanercept are equal alternatives for AR treatment and both were well tolerated.  
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Introduction 
 
Rheumatoid arthritis (RA) is a systemic, chronic and progressive inflammatory disease which affects 
the synovial membrane of joints, and which may lead to bone and cartilage destruction [1]. It is one of 
the more common autoimmune disorders estimated to affect between 0.3 and 1% of the worldV¶ 
population [2, 3]. In Brazil, a multicenter study found adult RA prevalence between 0.2 to 1% of the 
population [4], with a further Brazilian study performed in Montes Claros (Minas Gerais) finding a 
prevalence of 0.46% [5].  
 
Treatment of RA includes non-steroidal anti-inflammatory drugs, systemic or intra-articular 
glucocorticoid, conventional synthetic (sDMARDs) and biological (bDMARDs) disease-modifying 
antirheumatic drugs. Despite being effective in alleviating the symptoms of RA, bDMARDs are typically 
indicated for patients with persistent disease activity despite sDMARDs in view of their expense [6-8].   
 
In Brazil, all citizens are entitled to universal and equal access to services directed towards the 
promotion, protection and recovery of health [9]. Consequently the State must, indirectly, by way of 
public policies, and directly, by the Public Health System (SUS), provide complete treatment, including 
pharmaceutical care for patients with RA [10].   
 
The bDMARDs for the treatment of patients with RA were included in the Specialized Pharmaceutical 
Assistance Component (CEAF) of SUS from 2002 onwards, initially with infliximab. Adalimumab and 
etanercept were included from 2006 onwards [11, 12]. Access to these expensive medicines in CEAF 
depends on compliance with the Clinical Protocols and Therapeutic Guidelines (CPTGs) published by 
the Ministry of Health; otherwise 100% patient co-payment for the medicines [13]. Requests for access 
to these high cost medicines are checked by each State Department of Health or those contracted to 
them such as the SUS Collaborating Centre ± Health Technology Assessment & Excellence at the 
College of Pharmacy, Federal University of Minas Gerais.  
 
Adalimumab and etanercept were the most used bDMARDs in Brazil [14]. Information about the 
effectiveness and safety, in a context of scarcity of resources where priorities need to be established, 
awareness of the effectiveness of these medicines provided by the SUS in routine clinical practice 
need to be ascertained as the first step in assessing their future value. Consequently, the objective of 
this study was to evaluate the comparative effectiveness of adalimumab and etanercept in routine 
clinical practice in Brazil, through an open prospective cohort of patients with RA, approved for their 
use within the SUS. This is important given the diversity of patients attending specialist centres in 
Brazil. 
 
Methods 
 
The study population comprised patients diagnosed with RA, classified according to the American 
College of Rheumatology (ACR) criteria, who were treated with bDMARD by SUS. The date of first 
dispensation was defined as the first day of inclusion in the cohort since patients need to have their 
prescription approved by State Department of Health before they can receive any bDMARD. The 
cohort was initiated in March 2011, and patients were followed-up at six and 12 months.  
 
A standardized research form was developed documenting the medicines used, co-morbidities, the 
disease activity composite index, SDWLHQWV¶functionality and an assessment of their quality of life. The 
research forms were piloted to ascertain and address particular problems such as the wording of the 
questions, ordering and questionnaire layout. The patient interviews were subsequently performed 
face to face in SUS pharmacies at three time points. The interviews were conducted by Pharmacy 
postgraduate students of Federal University of Minas Gerais who had received training from 
rheumatologists in all pertinent aspects of the management of patients with RA. The first interview was 
conducted at the first dispensing of treatment for RA, the second interview at six months from the first 
interview and third interview at six months following the second interview.  
 
At baseline, the socio-demographic features were collected. The Clinical Disease Activity Index 
(CDAI), the Health Assessment Questionnaire (HAQ) and the EuroQol-5D (Eq-5D) were also 
assessed at baseline, and subsequently at six and 12 months. The CDAI is a clinical index of disease 
activity which evaluates painful and swollen joints, as well as assessing disease activity by the patient 
and physician. The clinical index range is 0-76, with the following classification systemUHPLVVLRQ
ORZGLVHDVHDFWLYLW\PRGHUDWHGLVHDVHDFWLYLW\DQd high disease activity > 22 [15]. The 
HAQ assesses the patient´s functionality through a self-administered questionnaire containing 20 
questions related to the difficulty in performing daily activities [16].  The EQ-5D was also used as it is a 
generic indicator of the SDWLHQW¶Vhealth condition through assessing five dimensions: mobility, personal 
care, usual activities, pain/discomfort and anxiety/depression, and additionally a visual analogue scale 
of their health condition [17, 18].  
 
The CDAI was subsequently used to assess the effectiveness of both bDMARDs by examining 
changes in the index value between baseline, six and 12 months follow-up. The bDMARDs were 
considered effective when the patient achieved remission or low disease activity, and considered 
ineffective when there was still moderate or high disease activity at 12-months. The association 
between socio-demographic and clinical characteristics, with disease activity measured by the CDAI, 
was also investigated. Frequency distributions were compiled for the socio-demographic variables and 
the mean and standard deviation was used for clinical variables.  Normality was assessed using the 
Kolmogorov Smirnov test and all measures are normally distributed [19]. Normally distributed 
continuous variables were compared XVLQJ6WXGHQW¶VW-test, and Pearson's chi-square was used for 
categorical variables. The paired Student T-test was established to evaluate the differences between 
the averages of the measurement of the disease activity (CDAI) within the three interviews.  Pearson's 
chi-square was applied for the univariate analysis to evaluate the association of effectiveness 
measured by the CDAI with the socio-demographic (gender, education, marital status and race) and 
clinical variables (type of drug, Eq-5D and HAQ).  Logistic regression was applied in the multivariate 
analysis of the variables that presented a p< 0.20 value during the univariate analysis. The SPSS 
Software (Statistical Package for Social Sciences) version 19.0, was used (IBM, Chicago, Illinois, 
USA). 
 
The study was approved by the Research Ethics Committee of the Federal University of Minas Gerais 
(COEP-UFMG) under No 0069.0.203.000 -11. 
 
Results 
 
Participants 
 
Two hundred sixty-six patients started treatment with adalimumab or etanercept, of whom 196 and 
151 completed 6 and 12 months of follow-up, respectively.  The reason for withdraw was impossibility 
of telephone contact, adverse events, barriers to attending the health service,  treatment failure, 
among others (Figure 1).  .  
 
Figure 1 ± Follow-up and withdrawal of AR patients at six and 12 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 patients withdraw the treatment 
 
(13) adverse events 
(8) therapeutic failure 
(7) change of bDMARDs 
(7) impossibility of telephone contact 
(5) barriers to attending the health service 
(5) refused to participate 
 
 
196 completed six months of follow-up 
 
143 adalimumab (73%) 
53 etanercept (27%) 
70 patients withdraw treatment 
 
(19) impossibility of telephone contact 
(14) adverse events 
(12) barriers to attending the health service 
(8) change of bDMARDs 
(7) refused to participate 
(5) therapeutic failure 
(2) not starded the treatment 
(1) difficulty of administering the drug 
(1) desire to get pregnant  
(1) changed doctor 
 
266 patients started treatment  
 
187 adalimumab (70%) 
79 etanercept (30%) 
 
151 completed 12 months of follow-up 
 
109 adalimumab (72%) 
42 etanercept (28%) 
 
The mean age of patients was 54.36 years (SD± 14.70) and the mean disease duration was 10.33 
years (SD± 88.64). Additionally, 88% of the patients were female, 46% white and 59% married. The 
most widely used bDMARD was adalimumab (70%), with etanercept used by 30 %.  
 
There were no statistically significant differences between the patient cohorts who used etanercept 
and adalimumab with regards to the baseline variables, except for duration of the disease, prior 
exposure to bDMARDs,  and CDAI (Table 1). 
 
Table 1 - Baseline of RA patients treated with adalimumab and etanercept. 
Characteristics 
Total           
(266) 
Adalimumab         
(187) 
Etanercept     
(79) 
P Value Á 
Age, mean ±  years 54.36 ± 14.70 54.48 ± 14.90 54.06 ± 14.31 0.833 
 
Duration of the disease, average ±  years 10.33 ± 8.64 9.63 ± 7.82 11.97 ± 10.20 0.043* 
Women (%) 233 (88) 166 (89) 67 (85) 0.371 
Race         
      White (%) 122 (46) 85 (46) 37 (47) 0.958 
      Brown (%) 103 (39) 72 (39) 31 (39)   
      Black (%) 32 (12) 23 (12) 9 (11)   
Marital Status       0.424 
Married (%) 157 (59) 110 (59) 47 (60)   
      Single (%) 61 (23) 40 (21) 21 (27)   
Education       0.527 
Uptoeightyears 93 (35) 65 (35) 28 (35)   
Aboveeightyears 170 (64) 119 (64) 51 (65)   
CurrentDrugs         
Methotrexate (%) 123 (46) 84 (45) 39 (49) 0.506 
Leflunomide (%) 110 (41) 81 (43) 29 (37) 0.317 
V'0$5' 202 (76) 140 (75) 62 (79) 0.529 
Corticosteroid (%) 208 (78) 148 (79) 60 (76) 0.564 
NSAIDs (%) 93 (35) 66 (35) 27 (34) 0.861 
PreviousDrugs         
sDMARD  (%) 257 (97) 179 (96) 78 (99) 0.214 
bDMARD (%) 38 (14) 19 (10) 19 (24) 0.003* 
ClinicalMeasurements         
CDAI, mean ±  25.11 ± 15.10 23.79 ± 14.54 28.22 ± 16.01 0.028* 
HAQ, mean ±  1.44 ± 0.67 1.41 ± 0.67 1.52 ±0.66 0.235 
Eq-5D, mean ±  0.58 ±0.18 0.58 ± 0.18 0.57 ±0.17 0.529 
 
NB: SD: standard deviation; sDMARD: synthetic disease-modifying antirheumatic drugs; NSAID: non-steroidal 
anti-inflammatory drug; bDMARD: biological disease-modifying antirheumatic drugs; CDAI: clinical disease 
activity index; HAQ: health assessment questionnaire; Eq-5d: EuroQol-5D. 
Áp value for etanercept x adalimumab  
*p<0.05 
 
  
Follow-up at six and 12 months  
 
At baseline, 78% patients were using corticosteroids, 35% were using NSAIDs and 76% were using 
DMARDs; during the follow-up, the frequency of concomitant therapy dropped, except for NSAID. 
There were no statistically significant differences between adalimumab and etanercept  regarding use 
of concomitant drugs at six and 12 months, except for methotrexate  concomitant use (p<0.05). (Table 
2). 
 
Table 2 - Use of therapeutic drugs by patients with RA at baseline and 6 and 12 months  
 
Concomitant drug 
6 months (196) 12 months (151) 
Total n(%) 
Adalimumab 
(143) 
Etanercept 
(53) valor p Total n(%) 
Adalimumab 
(109) 
Etanercept 
(42) valor p 
Corticosteroid  133 (68) 96 (67) 37 (70) 0.721 103 (68) 75 (70) 28 (67) 0.800 
NSAID 70 (36) 49 (34) 21 (40) 0.487 52 (34) 40 (37) 12 (29) 0.346 
SDMARD 130 (66) 91 (64) 39 (74) 0.191 100 (66) 69 (63) 31 (74) 0.221 
   Methotexate 69 (35) 42 (29) 27 (51) 0.005* 58 (38) 34 (31) 24 (57) 0.003* 
   Leflunomide 60 (31) 49 (34) 11 (21) 0.068 41 (27) 33 (30) 8 (19) 0.165 
DMARD: synthetic disease-modifying antirheumatic drugs; NSAID: non-steroidal anti-inflammatory drug 
*p<0.05 
 
The mean CDAI values at baseline and following six and 12 months of drug use were: 25.11 (SD± 
15.10); 14.42 (SD± 12.79) and 15.03 (SD± 14.19), respectively. Statistically significant differences 
were observed for the average CDAI values between the baseline and six months (p<0.001) and the 
baseline and 12 months (p<0.001) These data were normally distributed using the kolmogorov-
Smirnorv test. 
 
The mean CDAI value at six months was 13.91 (SD± 12.63) and 15.81 (SD± 13.22) for adalimumab 
and etanercept, respectively (p=0.357). At 12 months, the mean CDAI value was 14.92 (SD± 12.97) 
for adalimumab and 15.30 (SD± 17.14) for etanercepet (p=0.883) (Figure 2). 
 
Figure 2 ± Mean CDAI effectiveness of adalimumab and etanercept during a one-year of follow-up 
 
 
 
 
Taking the two bDMARDs together, the number of patients achieved clinical remission  were 31 (16%)  
at six months and 28 (19%) at 12 months. Furthermore, 59 (30%) and 41 (27%) patients achieved low 
disease activity at six and 12 months, respectively. Overall, the bDMARDs were effective for a total of 
90 (46%) and 69 (46%)  patients who achieved remission or low disease activity at six and 12 months, 
respectively. The bDMARDs were classified as not effective for the remaining patients. No statistically 
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significant differences in effectiveness were observed between adalimumab and etanercept at six 
(p=0.162) and 12 months (p=0.306) (Figure 3). 
 
Figure 3 - Patients who achieved remission and low disease activity (LDA) of adalimumab and 
etanercept at 6 and 12 months 
 
 
 
At 12 months of the study, 269 adverse events were reported by 108 (71.5%) patients, with the most 
common being application site reaction (19.9%), headache (19.2%), nausea (17.9%) and alopecia 
(15.9). A number of cases of infection were observed, including 19 upper respiratory infections, 15 
urinary tract infections, six fungal infections and three pneumonia at 12 months. The frequency 
distribution of most adverse events remained approximately constant at 6 and 12 months (Table 3). 
 
Table 3 - Adverse events reported by patients with RA at six and 12 months  
 
Adverse events 
6 months (196) 12 months (151) 
Total n (%) 
Adalimumab 
n (%) 
Etanercept 
n (%) Total n (%) 
Adalimumab 
n (%) 
Etanercept 
n (%) 
Application site reaction 50 (26) 33 (23) 17 (32) 30 (20) 18 (17) 12 (29) 
Headache 39 (20) 31 (22) 8 (15) 29 (19) 24 (22) 5 (12) 
Nausea 32 (16) 26 (18) 6 (11) 27 (18) 21 (19) 6 (14) 
Alopecia 29 (15) 23 (16) 6 (11) 24 (16) 19 (17) 5 (12) 
Upper respiratory infection 15 (8) 9 (6) 6 (11) 19 (13) 13 (12) 6 (14) 
Influenza 30 (15) 21 (15) 9 (17) 17 (11) 10 (9) 7 (17) 
Hypertension 22 (11) 20 (14) 2 (4) 16 (11) 12 (11) 4 (10) 
Urinary tract infection 24 (12) 17 (12) 7 (13) 15 (10) 12 (11) 3 (7) 
Pruritus 29 (15) 22 (15) 7 (13) 14 (9) 9 (8) 5 (12) 
Asthenia 23 (12) 16 (11) 7 (13) 14 (9) 9 (8) 5 (12) 
Rash 21 (11) 19 (13) 2 (4) 10 (7) 9 (8) 1 (2) 
Migraine 5 (3) 3 (2) 2 (4) 8 (5) 4 (4) 4 (10) 
Fever 8 (4) 6 (4) 2 (4) 8 (5) 6 (6) 2 (5) 
Fungal infection 4 (2) 1 (1) 3 (6) 6 (4) 5 (5) 1 (2) 
 
Predictors of effectiveness of bDMARDs measured by the CDAI 
 
Analyzing the association between effectiveness (CDAI) at 12 months with socio-demographic and 
clinical baseline variables identified a statistically significant difference in education status. Biological 
DMARDs were more effective at 12 months in patients who had spent a longer time in education (> 8 
Remission LDA
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12 months
yrs).  They were also more effective in patients which presented better functionality (HAQ less than 
one) than patients presented poor functionality (HAQ greater than two).  Sex, race, marital status, type 
of drug (corticosteroids, NSAIDs, sDMARD and previous bDMARD), the patient's age, duration of 
disease and quality of life did not prove to be predictors of effectiveness (Table 4). 
 
Table 4 - Predictive baseline characteristics of effectiveness response at 12 months 
 
Baseline 
characteristics 
  Effective      Not effective     Univariate  Multivariate 
  n       n (%) n (%) Value p OR 
Value 
p 
95% CI 
Sex               
Female 134 58 (43) 76 (57) 0.095       
Male 17 11 (65) 6 (35)         
Race               
White 64 31 (48) 33 (52) 0.611       
Brown 57 25 (44) 32 (56)         
Black 22 11 (50) 11 (50)         
Education               
Up to 8 years 51 16 (31) 35 (69) 0,012* Ref 
  Above 8 years 100 53 (53) 47 (47) 
 
2.087 0.049* [1.002;4.346] 
Age in years               
<HDUV 52 25 (48) 27 (52) 0.670       
>50 Years 99 44 (44) 55 (56)         
Period of 
disease               
<HDUV 29 14 (48) 15 (52) 0.756       
>3 Years 122 55 (45) 67 (55)         
Prior bDMARD               
Yes 22 9 (41) 13 (59) 0.626       
No 129 60 (47) 69 (53)         
sDMARD               
None 37 15 (41) 22 (59) 0.469       
More than one 114 54 (47) 60 (53)         
Corticosteroids               
Yes 120 52 (43) 68 (57) 0.252       
Not 31 17 (55) 14 (45)         
NSAID               
Yes 56 22 (39) 34 (61) 0.225       
Not 95 47 (50) 48 (50)         
HAQ               
0 a 1 37 23 (62) 14 (38)  0.016* Ref 
 
  
1 a 2 87 39 (45) 48 (55)   1.903 0.114 [0.856;4.227] 
2 a 3 27 7 (26) 20 (74) 
 3.807 0.019* [1.249;11.602] 
EQ-5D               
 94 40 (43) 54 (57) 0.320       
>0.6 57 29 (51) 28 (49)         
NB: OR: odds ratio; sDMARD: synthetic disease-modifying antirheumatic drugs; NSAID: non-steroidal anti-
inflammatory drug; bDMARD: biological disease-modifying antirheumatic drugs; HAQ: health assessment 
questionnaire; Eq-5D: EuroQol-5D. NR: not reported. *p<0.05 
 
Discussion 
 
Both bDMARDs, adalimumab and etanercept, reduced disease activity as measured by CDAI at six 
and 12 months.  However, no statistically significant difference (p<0.05) was observed between them 
for remission and low disease activity at 6 and 12 months. The bDMARDs were well tolerated and 
effective in almost half of the patients, who achieved the target of remission or low disease activity 
according to CDAI. bDMARDs were more effective in patients who presented with better functionality 
(HAQ less than one) at treatment onset, and  had spent a longer time in education (> 8 yrs).   
 
Recent systematic reviews of randomized clinical trials and cohort studies which assessed the efficacy 
and effectiveness of the bDMARDs also reported no differences between adalimumab and etanercept 
with outcomes measured with either (i) the Disease activity score (DAS 28); (ii) European League 
Against Rheumatism (EULAR) scores; (iii) ACR 20, 50, 70; (iv) CDAI remission, or (v) Simplified 
disease activity index (SDAI) [20-23]. However, others systematic reviews evaluated efficacy of 
randomized clinical trials with ACR 20, 50 and 70 and reported that etanercept was better than 
adalimumab [24-26], except one study related that adalimumab was better than etanercept [27].  
 
Published clinical trials studies with etanercept have shown 46.2% efficacy (remission and low disease 
activity) at 24 weeks as measured by the CDAI [328], with similar findings seen in our study. Other 
clinical trials with etanercept have also shown remission of 8.5% and 39% for etanercept at 24 weeks 
and three years, respectively [28, 29]. Observational studies have reported similar effectiveness at 24 
weeks to that seen in our study for etanercept [30], and similar CDAI remission (18 %) to our study 
when patients with RA were treated with adalimumab or etanercept for 12 months [31-33]. However, 
other studies have documented greater remission as measured by the CDAI for treatment with 
etanercept (35%) at three years and for adalimumab (27%) at 12 weeks [29, 34]. 
 
The effectiveness of adalimumab decreased in our study probably due to production of autoantibodies 
that was reported in other studies [35,36], but it was not possible to analyze the production of 
autoantibodies with the data obtained in this cohort study. On the other hand, the increased 
effectiveness of etanercept should be analysed with caution, because  a higher proportion of patients 
withdrawing from treatment between six and 12 months had higher CDAI. Thus the patients who 
presented a lower level of disease activity remained in the study, impacting on the increase of the 
effectiveness for this drug. 
 
Cohort studies have reported that sex, age, duration of disease, the number of prior sDMARDs and 
concurrent non-steroidal anti-inflammatory at the baseline do not influence the response to treatment, 
and similar results were observed in this study. Others studies using HAQ as a prognostic indicator of 
effectiveness have shown that better functionality at treatment onset is associated with a greater 
response to treatment [37-39]. This was also shown in our study beyond the observation that the 
bDMARDs were more effective at 12 months in patients who had spent a longer time in education (> 8 
yrs).  
 
The treatment with adalimumab and etanercept were well tolerated by patients in this cohort. 
Application site reaction, headache, nausea and alopecia was the most common adverse events that 
was similar to those described in other studies [40,41]. A number of cases of infection were observed, 
including 19 upper respiratory infections, 15 urinary tract infections, six fungal infections and three 
pneumonia at 12 months. Infections should be a major cause for concern among the adverse 
reactions, because there is evidence that the possibility of the patients had serious infections tend to 
increase with bDMARDs [42]. 
 
Overall, half of the patients in this study did not achieve the target with bDMARDs. In this situation 
various international bodies, including the European League Against Rheumatism, the American 
College Rheumatology and the Clinical Protocol and Therapeutic Guidelines for RA in Brazil, 
recommend replacement of current bDMARDs [43-45].  
 
However in current clinical practice in Brazil, there are a difficulties with continuous pharmaco-
therapeutic monitoring and on access to medicines under SUS (i.e. only infliximab, etanercept and 
adalimumab were provided by the SUS until the end of 2013), which may be a possible explanation for 
the maintenance of current bDMARDs in our study even in those patients who have not achieved the 
treatment target. In such cases, before the replacement of current bDMARDs, additional pharmaco-
therapeutic monitoring should be encouraged to identify the reasons for treatment failure or lack of 
effectiveness and adverse events DVSDUWRID³WUHDW-to-WDUJHW´VWUDWHJ\.  The "treat-to-target" is defined 
as a treatment strategy in which the clinician treats the patient aggressively, adopting as a target 
either remission or low disease activity. This strategy enables the physician and the patient to discuss 
and adopt therapeutic changes within the required period of time [46, 47]. Studies have reported that 
this strategy has become increasingly important in clinical practice to improve remission rates [48-50]. 
Other professionals, such as nurse and pharmacists, could also act together with rheumatologists and 
consider patient choices in order to facilitate the implementation of a "treat-to-target" strategy [51, 52]. 
We will be investigating this in the future. 
 
Limitations 
 
We are aware this study was conducted during the daily dispensing of medicines within the SUS and 
some biases could not be controlled. The patients were not randomized, and treatment was 
administered in accordance with the rheumatologist´s prescriptions. The study was also performed 
under real-life conditions (without a control group), thus differences were observed in the number of 
participants among the groups, the group of etanercept was smaller than adalimumab. In addition, 
there was also no routine data collection of autoantibodies (RF, ACPAs) or no routine collection of 
laboratory data such as ESR or CRP. This though reflects reality in real-life studies undertaken with 
SUS patients in Brazil. 
 
However we believe this study is important in order to supplement the results of clinical trials, as it 
demonstrates the effectiveness of the bDMARDs in routine clinical practice within a Brazilian 
population. The routine use of a CDAI measure is practical and objective as it does not require 
laboratory data for its calculation. Moreover, it has presented good to moderate correlations with other 
clinical indicators of disease activity (DAS 28, EULAR and ACR) [15, 53-56].  
 
Conclusion 
 
Only half of the patients achieved the treatment target of remission or low disease activity with either 
adalimumab or etanercept. No statistically significant differences were observed between them.The 
remaining patients should have their therapeutic options reviewed over these 12 months. The 
treatment with adalimumab and etanercept were well tolerated. In addition, bDMARDs were more 
effective in patients who had spent a longer time in education (> 8 yrs) and presented better 
functionality at treatment onset as measured by the HAQ.  
In view of the high cost of the bDMARDs to SUS and, consequently, to society, versus sDMARDs 
continuous pharmaco-therapeutic monitoring should be performed by a multidisciplinary team. This 
could achieve better results, assuring the quality of use of the bDMARDs. Further studies should focus 
on important issues like adherence and costs, especially factors that might affect persistence as this 
will appreciably impact on the long term effectiveness and costs of medicines to treat this chronic 
condition. 
 
Executive Summary 
 
x 266 RA patients started treatment with adalimumab or etanercept, of whom 196 and 151 
completed 6 and 12 months of follow-up, respectively  The most widely used bDMARD was 
adalimumab (70%), with etanercept used by 30% of patients. 
 
x The percentage of patients achieving remission or low disease activity was 46%, with no 
difference in effectiveness between adalimumab and etanercept (p=0.306) 
 
 
x Patients who had not achieved the treatment target of disease remission or low disease activity 
remained in treatment at 12 months. They should have their therapeutic options regularly 
reviewed 
 
x The treatment with adalimumab and etanercept were well tolerated. 
 
x Overall, the bDMARDs were more effective in patients who had better disease functionality (HAQ 
less than one) at treatment onset, and had spent a longer time in education (> 8 yrs) 
 
 
x Additional pharmaco-therapeutic monitoring should be encouraged to identify the reasons for 
treatment failure or lack of effectiveness and adverse events DVSDUWRID³WUHDW-to-WDUJHW´VWUDWHJ\ 
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